# Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy "PROBE"

> **NCT01935466** · — · COMPLETED · sponsor: **Post Graduate Institute of Medical Education and Research, Chandigarh** · enrollment: 6107 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT01935466
- **Lead sponsor:** Post Graduate Institute of Medical Education and Research, Chandigarh
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2021-10
- **Final completion:** 2021-10
- **Target enrollment:** 6107 (ACTUAL)
- **Last updated:** 2022-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01935466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01935466, "Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy "PROBE"". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01935466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*